Search results for "cancer treatment"

showing 10 items of 133 documents

The EndoPredict Gene-Expression Assay in Clinical Practice - Performance and Impact on Clinical Decisions

2013

The validated EndoPredict assay is a novel tool to predict the risk of metastases of patients with estrogen receptor positive, HER2 negative breast cancer treated with endocrine therapy alone. It has been designed to integrate genomic and clinical information and includes clinico-pathological factors such as tumor size and nodal status. The test is feasible in a decentral setting in molecular pathology laboratories. In this project, we investigated the performance of this test in clinical practice, and performed a retrospective evaluation of its impact on treatment decisions in breast cancer. During one year, EndoPredict assays from 167 patients could be successfully performed. For retrospe…

OncologyNon-Clinical Medicinemedicine.medical_treatmentCancer Treatmentlcsh:MedicineEstrogen receptorBioinformaticsMetastasisSurveys and QuestionnairesPathologylcsh:ScienceMultidisciplinaryMolecular pathologyCancer Risk FactorsHormonal TherapyObstetrics and GynecologyEndocrine TherapyMiddle AgedOncologyReceptors EstrogenCohortMedicineFemaleRisk assessmentMolecular PathologyResearch ArticleAdultmedicine.medical_specialtyAntineoplastic Agents HormonalGenetic Causes of CancerClinical Decision-MakingBreast NeoplasmsRisk AssessmentBreast cancerDiagnostic MedicineInternal medicineBreast CancermedicineHumansAgedRetrospective StudiesChemotherapyHealth Care Policybusiness.industryGene Expression Profilinglcsh:RHealth Risk AnalysisRetrospective cohort studyChemotherapy and Drug Treatmentmedicine.diseaselcsh:QbusinessGeneral PathologyPLoS ONE
researchProduct

Nitric Oxide and Platinum-Derivative-Based Regimens for Cancer Treatment: From Preclinical Studies to Clinical Trials

2017

Abstract Chemoresistance to platinum-based antitumor agents remains a major hindrance faced by patients with a wide variety of solid tumors. New effective strategies are still needed to improve chemosensitization and overcome chemoresistance of tumors by platinum-based chemotherapies. Over the past decade, considerable knowledge on the antitumor effect of nitric oxide (NO) and its mechanisms of action has been gained. Here, we provide an overview of the basic mechanisms of resistance to platinum-based drugs and how NO can bypass this chemotherapy resistance. Preclinical and clinical studies focused on combination therapy using platinum chemotherapeutic drugs with NO donors have demonstrated…

Oncologymedicine.medical_specialtyCombination therapybusiness.industryCancerchemistry.chemical_elementPharmacologymedicine.diseaseCancer treatmentNitric oxideNo donorsClinical trialchemistry.chemical_compoundchemistryChemosensitizationInternal medicinemedicinebusinessPlatinum
researchProduct

Endocrine side-effects of new anticancer therapies: Overall monitoring and conclusions

2018

IF 0.795 (2017); International audience; The present final consensus statement of the French Society of Endocrinology lays out the assessments that are to be systematically performed before and during anticancer treatment by immunotherapy, tyrosine kinase inhibitors or mTOR inhibitors, even without onset of any endocrinopathy. It also discusses the CTCAE adverse event grading system in oncology and the difficulty of implementing it for endocrine side-effects of these anticancer treatments. Notably, this is why certain treatment steps applied in other side-effects (e.g., high-dose corticosteroids, contraindications to immunotherapy, etc.) need to be discussed before implementation for endocr…

Oncologymedicine.medical_specialtyConsensusEndocrinology Diabetes and Metabolismmedicine.medical_treatmentAntineoplastic Agents030209 endocrinology & metabolism[SDV.CAN]Life Sciences [q-bio]/CancerEndocrine System Diseases03 medical and health sciences0302 clinical medicineEndocrinologyDysthyroidismNeoplasmsInternal medicineAnimalsHumansMedicineEndocrine systemHypophysitisAdverse effectMTOR inhibitorsTyrosine kinase inhibitorsAdrenal failurebusiness.industryDiabetesGeneral MedicineImmunotherapy[SDV.MHEP.EM]Life Sciences [q-bio]/Human health and pathology/Endocrinology and metabolismDiscovery and development of mTOR inhibitors3. Good healthDyslipidemiaAnticancer treatment030220 oncology & carcinogenesisAdrenal failureImmunotherapybusiness
researchProduct

Retrospective Study of Regorafenib Versus TAS-102 Efficacy and Safety in Chemorefractory Metastatic Colorectal Cancer (mCRC) Patients: A Multi-instit…

2021

INTRODUCTION: There have been significant developments in colorectal cancer (CRC) research over the last few years, with the introduction of new agents that have been prolonged median overall survival of metastatic colorectal cancer (mCRC). These therapies have improved patient outcomes; however, despite significant progress in strategies for cancer treatment, their use is limited by development of resistant mechanism. Almost 30% of patients with refractory mCRC will remain good candidates for further treatment. Regorafenib and TAS-102 are novel antitumor agents for patients with refractory mCRC. However, it is unclear which patients may derive a survival benefit from these drugs in real-li…

Oncologymedicine.medical_specialtyPyrrolidinesReal Life Clinical dataPyridinesColorectal cancerTrifluridinechemistry.chemical_compoundRefractoryInternal medicineRegorafenibmedicineHumansUracilRetrospective Studiesbusiness.industryPhenylurea CompoundsGastroenterologyRetrospective cohort studymedicine.diseaseTAS-102Disease controlCancer treatmentClinical trialDrug CombinationsOncologychemistrymCRCCohortchemorefractoryregorafenibColorectal NeoplasmsbusinessThymine
researchProduct

S-Adenosylmethionine Supplementation May Reduce Cancer-Related Fatigue: A Prospective Evaluation Using the FACIT-F Questionnaire in Colon Cancer Pati…

2021

<b><i>Background:</i></b> Fatigue is a common distressing symptom for patients living with chronic or acute diseases, including liver disorders and cancer (<i>Cancer-Related Fatigue</i>, CRF). Its etiology is multifactorial, and some hypotheses regarding the pathogenesis are summarized, with possible shared mechanisms both in cancer and in chronic liver diseases. A deal of work has investigated the role of a multifunctional molecule in improving symptoms and outcomes in different liver dysfunctions and associated symptoms, including chronic fatigue: S-adenosylmethionine (SAM; AdoMet). The aim of this work is actually to consider its role also in oncologic…

Oncologymedicine.medical_specialtyS-AdenosylmethionineBevacizumabCancer-related fatigueColorectal cancerAdoMetFOLFOXInternal medicineSurveys and QuestionnairesDrug DiscoverymedicineHumansPharmacology (medical)Cancer-related fatigueFatiguePharmacologybusiness.industryCancerChronic fatigueGeneral Medicinemedicine.diseaseCancer treatment toxicityOxaliplatinColon cancerOxaliplatinRegimenInfectious DiseasesOncologyFunctional Assessment of Chronic Illnesses Therapy-FatigueColonic NeoplasmsDietary SupplementsQuality of Lifemedicine.symptombusinessmedicine.drugChemotherapy
researchProduct

Osteonecrosis of the jaw in the era of targeted therapy and immunotherapy in oncology

2019

Osteonecrosis of the jaw (ONJ) is a well-known pathological condition in oncology derived from the use of bisphosphonates (BPs) and denosumab. Many molecular and immunological targets have been introduced for daily use in cancer treatment in recent years; consequently, new cases of ONJ have been reported in association with these drugs, especially if administered with BPs and denosumab. When the drugs are administered alone, ONJ is rarely seen. The objective of our study was to analyze the recent literature relative to the association of ONJ with these new drugs highlighting the pathogenic, clinical and therapeutic aspects. The close collaboration between maxillofacial surgeon, oncologist, …

Oncologymedicine.medical_specialtymedicine.medical_treatmentOdontologíaReview ArticleMaxilaresTargeted therapyOncologíaImmunomodulation03 medical and health sciences0302 clinical medicineInternal medicinemedicineOral manifestations030223 otorhinolaryngologyBonePathologicalbusiness.industryGénéralités030206 dentistryImmunotherapyCáncermedicine.diseaseCancer treatmentDenosumabSurgeryOral SurgeryOsteonecrosis of the jawbusinessAngiogenesis modulatorsInfectionmedicine.drug
researchProduct

Do Patients with Luminal A Breast Cancer Profit from Adjuvant Systemic Therapy? A Retrospective Multicenter Study

2016

Background Luminal A breast cancers respond well to anti-hormonal therapy (HT), are associated with a generally favorable prognosis and constitute the majority of breast cancer subtypes. HT is the mainstay of treatment of these patients, accompanied by an acceptable profile of side effects, whereas the added benefit of chemotherapy (CHT), including anthracycline and taxane-based programs, is less clear-cut and has undergone a process of critical revision. Methods In the framework of the BRENDA collective, we analyzed the benefits of CHT compared to HT in 4570 luminal A patients (pts) with primary diagnosis between 2001 and 2008. The results were adjusted by nodal status, age, tumor size and…

Oncologymedicine.medical_treatmentCancer Treatmentlcsh:MedicineBiochemistry0302 clinical medicineBreast TumorsMedicine and Health Sciences030212 general & internal medicinelcsh:ScienceAged 80 and overMultidisciplinaryPharmaceuticsHormonal TherapyEndocrine TherapyMiddle AgedSurvival RateOncologyChemotherapy Adjuvant030220 oncology & carcinogenesisFemaleAnatomyResearch Articlemedicine.drugClinical OncologyAdultmedicine.medical_specialtyAnthracyclineBreast NeoplasmsDisease-Free SurvivalLymphatic System03 medical and health sciencesBreast cancerDrug TherapyDiagnostic MedicineInternal medicineBreast CancerCancer Detection and DiagnosismedicineChemotherapyHumansddc:610Survival rateGrading (tumors)AgedRetrospective StudiesChemotherapyTaxanebusiness.industrylcsh:RCancers and NeoplasmsBiology and Life SciencesRetrospective cohort studymedicine.diseaseHormonesSurgerylcsh:QLymph NodesClinical MedicinebusinessTamoxifenPLOS ONE
researchProduct

miR-205-5p-mediated downregulation of ErbB/HER receptors in breast cancer stem cells results in targeted therapy resistance

2015

AbstractThe ErbB tyrosine kinase receptor family has been shown to have an important role in tumorigenesis, and the expression of its receptor members is frequently deregulated in many types of solid tumors. Various drugs targeting these receptors have been approved for cancer treatment. Particularly, in breast cancer, anti-Her2/EGFR molecules represent the standard therapy for Her2-positive malignancies. However, in a number of cases, the tumor relapses or progresses thus suggesting that not all cancer cells have been targeted. One possibility is that a subset of cells capable of regenerating the tumor, such as cancer stem cells (CSCs), may not respond to these therapeutic agents. Accumula…

P63cancer stem cellsCancer ResearchReceptor ErbB-2oncogenesmedicine.medical_treatmentmedicine.disease_causeTargeted therapyERBB3Molecular Targeted TherapyDEATHErbB ReceptorsGene Expression Regulation NeoplasticNeoplastic Stem CellsFemaleOriginal Articlemedicine.drugCARCINOMAMIGRATIONCancer Stem Cells; Breast CancerImmunologyBreast NeoplasmsCancer Stem CellMIR-205miR-205-5pBiologyLapatinibcancer treatmentNOCellular and Molecular Neurosciencebreast cancerBreast cancerErbBCancer stem cellCell Line TumormedicineHumansSUPPRESSIONCell ProliferationMESENCHYMAL TRANSITIONtumorigenesis cancer treatment cancer stem cells miR-205-5p oncogenes breast cancerMICRORNA EXPRESSIONTumor Suppressor ProteinsLapatinibCell BiologyTrastuzumabmedicine.diseaseGENEMicroRNAstumorigenesisDrug Resistance NeoplasmCancer cellQuinazolinesCancer researchNeoplasm Recurrence LocalCarcinogenesisTranscription FactorsCell Death & Disease
researchProduct

Ultrasound-Guided Intramural Inoculation of Orthotopic Bladder Cancer Xenografts: A Novel High-Precision Approach

2013

Orthotopic bladder cancer xenografts are essential for testing novel therapies and molecular manipulations of cell lines in vivo. Current xenografts rely on tumor cell inoculation by intravesical instillation or direct injection into the bladder wall. Instillation is limited by the lack of cell lines that are tumorigenic when delivered in this manner. The invasive model inflicts morbidity on the mice by the need for laparotomy and mobilization of the bladder. Furthermore this procedure is complex and time-consuming. Three bladder cancer cell lines (UM-UC1, UM-UC3, UM-UC13) were inoculated into 50 athymic nude mice by percutaneous injection under ultrasound guidance. PBS was first injected b…

PathologyMouseTumor PhysiologyCancer Treatmentlcsh:MedicineMiceBasic Cancer ResearchMedicineUltrasonicslcsh:ScienceBladder Cancer and Urothelial Neoplasias of the Urinary TractMultidisciplinaryUltrasoundAnimal ModelsBladder CancerOncolytic VirusesOncologySurgery Computer-AssistedMedicineOncology AgentsFemaleImmunotherapyResearch Articlemedicine.drugmedicine.medical_specialtyClinical Research DesignUrologyTransplantation HeterologousModel OrganismsIn vivoCell Line TumorAnimalsHumansBioluminescence imagingddc:610Animal Models of DiseaseBiologyCell ProliferationCisplatinBladder cancerbusiness.industrylcsh:RCancers and NeoplasmsChemotherapy and Drug Treatmentmedicine.diseaseGemcitabineOncolytic virusTransplantationGenitourinary Tract TumorsUrinary Bladder NeoplasmsFeasibility Studieslcsh:QbusinessPLoS ONE
researchProduct

Late Cardiac Events after Childhood Cancer: Methodological Aspects of the Pan-European Study PanCareSurFup.

2016

Background and AimChildhood cancer survivors are at high risk of long-term adverse effects of cancer and its treatment, including cardiac events. The pan-European PanCareSurFup study determined the incidence and risk factors for cardiac events among childhood cancer survivors. The aim of this article is to describe the methodology of the cardiac cohort and nested case-control study within PanCareSurFup.MethodsEight data providers in Europe participating in PanCareSurFup identified and validated symptomatic cardiac events in their cohorts of childhood cancer survivors. Data on symptomatic heart failure, ischemia, pericarditis, valvular disease and arrhythmia were collected and graded accordi…

PediatricsCritical Care and Emergency MedicineCancer Treatmentlcsh:MedicineADULT SURVIVORSCHILDREN030204 cardiovascular system & hematologyDOXORUBICIN THERAPYPediatricsCohort Studies0302 clinical medicineRisk FactorsNeoplasmsMedicine and Health SciencesSurvivorsYoung adultChildlcsh:Scienceeducation.field_of_studyMultidisciplinaryGUIDELINE HARMONIZATION GROUPCancer Risk Factors3. Good healthEuropeOncologyHelminth Infections030220 oncology & carcinogenesisChild PreschoolCohortHEALTH OUTCOMESRecord linkageCohort studyResearch ArticleNeglected Tropical DiseasesAdultCARDIOTOXICITYmedicine.medical_specialtyAdolescentHeart DiseasesLONG-TERMPopulationCardiology610 Medicine & health03 medical and health sciencesYoung Adult360 Social problems & social servicesDiagnostic MedicineEchinococcosismedicineCancer Detection and DiagnosisParasitic DiseasesHumanseducationAdverse effectCONGESTIVE-HEART-FAILUREbusiness.industryMORTALITYlcsh:RCase-control studyCancerInfantmedicine.diseaseTropical DiseasesPediatric OncologyCase-Control StudiesRISK-FACTORSlcsh:QbusinessPLoS ONE
researchProduct